PolarityTE Inc.

PolarityTE — Investor Presentation (September 2020)

38 slides from PolarityTE's investor presentation, Sep 23, 2020

  1. Slide 1: PolarityTE: Where Self Regenerates Self

    Polarity TE" Where Self Regenerates Self” Ben

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements and projections. PolarityTE, Inc. (the "Company") makes no express or implied representation or warrant as to the completeness of this information or, in the case of projections, as to their attainability or the accurac

  3. Slide 3: PolarityTE, Inc. Key Company Highlights

    PolarityTE, Inc. Key Company Highlights + CLINICAL EXPERIENCE: More than 900 patients treated with SkinTE™—the Company's autologous skin construct intended for the repair, replacement, reconstruction, or supplementation of skin tissue + PUBLISHED EVIDENCE: 9 peer-reviewed publications on SkinTE, inc

  4. Slide 4: About PolarityTE, Inc.

    About PolarityTE, Inc. SkinTE Marketed as a 361 HCT/P Currently pursuing transition to a 351 HCT/P via Biologics License Application (BLA) Used in over 900 clinical cases 2 ongoing multi-center randomized controlled trials 9 peer-reviewed publications 4 patents issued worldwide ARCHES RESEARCH RAPID

  5. Slide 5: Current Treatment Options Have Significant Limitations

    Current Treatment Options Have Significant Limitations Scaffolds & Matrices Allogeneic/Xenogeneic Off the shelf and used in all settings Cells & Tissues of care + May contain cells and/or proteins to Lack cells and require wound bed to stimulate closure but are temporary {grow into the scatfold ‘+ R

  6. Slide 6: Split-Thickness Skin Graft Donor Sites

    Split-Thickness Skin Graft Donor Sites Split-Thickness Skin Grafts Split-Thickness Skin Graft Harvesting Skin Graft Donor Site 2 Years Following Harvest a

  7. Slide 7: Characteristics of Native Skin

    Characteristics of Native Skin Skin is much more than a single layer of cells providing a barrier—skin is the largest organ of the human body and requires regeneration of all components for normal function. + Sensation + Immunity + Sweating + Sebum + Hair growth + Pliability

  8. Slide 8: The SkinTE Solution

    The SkinTE Solution SkinTE is made from full-thickness skin and retains the endogenous regenerative cellular populations found throughout skin within multicellular segments. Research studies on swine and human tissue demonstrated that gene expression pathways and proteins important for wound healing

  9. Slide 9: How to Use SkinTE

    How to Use SkinTE SkinTE + Harvests can be performed out patient under local anesthesia, as well as in patient as required + Skin harvest is sent to Salt Lake City facility, typically overnight, and is capable of being processed on the same day for overnight delivery back to the provider + SkinTE is

  10. Slide 10: SkinTE Case Study: Chronic Lower Extremity Traumatic Wound

    SkinTE Case Study: Chronic Lower Extremity Traumatic Wound SkinTE Applied to Chronic Wound on Right Lower Extremity After Two Years of Failed Treatments Right Leg: Right Leg: Left Leg Before SkinTE After SkinTE STSG Multi-Modality Imaging of Hair Follicles Confocal Confocal Pr Merge Dual ESEM Stereo

  11. Slide 11: SkinTE Case Study: Replacement of STSG

    SkinTE Case Study: Replacement of STSG SkinTE Used to Replace Split-Thickness Skin Graft in Fibrotic Wound Bed = Inc, All Rights

  12. Slide 12: SkinTE: Designed to Increase and Expand Access

    SkinTE: Designed to Increase and Expand Access Broad Utilization: Broad Applications To Date in Acute Appropriate for Multiple Points of Care: and Chronic Wounds: Physicians including: ~ Surgical Specialties + Diabetic foot ulcers + Wound care centers and clnies = Non-Surgical Specialties + Venous l

  13. Slide 13: SkinTE in a Broad Spectrum of Wounds

    SkinTE in a Broad Spectrum of Wounds Pressure Injuries — Sacral Injury Traumatic Injury — Lawnmower Accident si Initial wound ks after single application of SkinTE Initial wound ~9 weeks after single 24 weeks after single application of SkinTE application of Traumatic Injury - Motor Vehicle Accident

  14. Slide 14: SkinTE in a Broad Spectrum of Wounds

    SkinTE in a Broad Spectrum of Wounds Diabetic Foot Ulcer Venous Leg Ulcer SSS Initial wound ~T weeks after single #9 weeks after'sngle Inital wound ~13 weeks after single application of SkinTE ‘application of Skin7E application of SkinTE [ atin single application of Post-debridement ~13 months after

  15. Slide 15: SkinTE Case Study: Non-Healing Diabetic Foot Ulcer

    SkinTE Case Study: Non-Healing Diabetic Foot Ulcer Patient Overview Day 0 — Before SkinTE SkinTE Application Day 10 The patient was a 57-year-old male with diabetes who presented with a long- standing left dorsal foot ulcer with exposed tendons that did not respond to prior debridement and therapies

  16. Slide 16: SkinTE Case Study: Chronic Lower Extremity Traumatic Wound

    SkinTE Case Study: Chronic Lower Extremity Traumatic Wound SkinTE Progression of Wound Closure Over 6 Months a f q Patient Overview 31-year-old male Presentation: + Chronic open wound History: + Injuries to both lower extremities from a motorcycle accident 2 years prior Prior management: + Skin graf

  17. Slide 17: SkinTE Total U.S. Market Opportunity

    SkinTE Total U.S. Market Opportunity SkinTE Total Addressable Market: $7.6B Chronic Wounds $4.27B References 1578 Burn 500k Patients Receiving Burn Treatment Per Year! 35k Patients Hospitalized Due to Burns Per Year! $73k — Weighted Average Cost to Treat Wounds! Total Addressable Market $2.55 Billio

  18. Slide 18: SkinTE U.S. Chronic Wound Market Opportunity

    SkinTE U.S. Chronic Wound Market Opportunity SkinTE Chronic Wound Addressable Market: $4.27B Diabetic Foot Ulcers $2.57B ‘References 9101412131615 1517.28 192021222824 Diabetic Foot Ulcers 34m Diabetic in the United States? 22m DFU Annual Incidence Rate® 4m Unhealed DFUs following 12 weeks of Conven

  19. Slide 19: Diabetic Foot Ulcers: Data and Statistics

    Diabetic Foot Ulcers: Data and Statistics Annual incidence rate of diabetics who develop a foot ulcer is 2.2%. However, higher annual incidence rates of ~6% have been reported in the Medicare population 25 The lifetime incidence of foot ulcers has previously been estimated to be 15% to 25% among per

  20. Slide 20: SkinTE DFU and VLU Pilot Data

    SkinTE DFU and VLU Pilot Data Diabetic Foot Ulcer (DFU) Pilot TriaP? Results presented at the Diabetic Limb Salvage Conference and the Symposium on Advanced Wound Care and The American Diabetes Association + 10.of 11 (90.9%) DFUs healed within 8 weeks of a single application of SkinTE Pilot Study Di

  21. Slide 21: Chronic Wound Trials

    Chronic Wound Trials Diabetic Foot Ulcer Randomized Clinical Trial: * 78 patients enrolled as of September 16, 2020 Venous Leg Ulcer Randomized Clinical Trial: + 29 of 50 patients enrolled for pre-specified interim analysis target as of September 16, 2020 d p po Enrollment Status ‘Status/ Outcomes D

  22. Slide 22: DFU Trial Design

    DFU Trial Design Prospective, multi-center, randomized controlled trial evaluating SkinTE plus standard of care (SOC) vs. SOC alone in the treatment of Diabetic Foot Ulcers (DFUs) Inclusion Criteria: * Wagner 1 Diabetic Foot Ulcer (DFU) below the medial malleolus * Index ulcer >1.0 cm? and <25 cm? a

  23. Slide 23: DFU Trial Design

    DFU Trial Design Primary Outcome Measure Percentage of wounds closed at 12 weeks defined as complete epithelialization without drainage or dressing requirements confirmed at two consecutive study visits 2 weeks apart Closure Determination Initial closure determined by treating provider and confirmed

  24. Slide 24: DFU Trial Design

    DFU Trial Design Secondary Outcome Measures: Percent area reduction (PAR) at 4, 6, 8, and 12 weeks as measured by 3D digital planimetry (eKare, Fairfax, VA) Quality of life comparison using Wound Quality of Life Score Pain assessment using Visual Analogue Pain Scale (VAS) pain scale Peripheral neuro

  25. Slide 25: DFU Interim Analysis: Demographics

    DFU Interim Analysis: Demographics Demographic Variable SkinTE soc Seta) Enrollment: Patient Age (yea) 616 (10.25) 593 03.46) osi_| * 25 SkinTE patients and 25 SOC patients cs 323 (7.56) 33.4 (754) 059 * 43 sites across the US Male " 18 (72) 7 (68) 076 Female 728) 8 (32) Subject Comorbidites 963.29)

  26. Slide 26: DFU Interim Analysis: SkinTE Met Primary Endpoint

    DFU Interim Analysis: SkinTE Met Primary Endpoint 100 —>SkinTE -®SOC 8 8 é Percentage of Wounds Closed 8 8 —— a = 0 1020 PolarityTE, inc. All Rights R 2 4 6 8 Time (Weeks from Randomization) SkinTE Group: 18/25 DFUs Closed at 12 Weeks (72%) SOC Group: 8/25 DFUs Closed at 12 Weeks (32%) p=0.005

  27. Slide 27: DFU Interim Analysis Secondary Endpoint: Percent Area Reduction

    DFU Interim Analysis Secondary Endpoint: Percent Area Reduction Percentage Area Reduction a ri 70 rr -SkinTE SOC 60 rid wd 40 A eS ol tA \ off \ if iy V 4 6 8 Time (Weeks from Randomization) olarityTE, Inc. All Rights Reserved. 10 12 Week SkinTE soc p-value 4 78.6 (35.6) 24.0 (106.52) 0.00021 6 | 83

  28. Slide 28: DFU Interim Analysis: Secondary Endpoints

    DFU Interim Analysis: Secondary Endpoints No Significant Difference: * Quality of life comparison using Wound Quality of Life Score + Pain assessment using Visual Analogue Pain Scale (VAS) pain scale at 12 weeks + Peripheral neuropathy assessment using Semmes-Weinstein Monofilament 10-point discrimi

  29. Slide 29: Patient Experience

    Patient Experience ih “My skin is smooth. The hairis actually growing back “If Lhad to choose between SkinTE and another skin graft | would choose SkinTE every time, because it is actually working, and you do not have a huge area of healthy skin removed that also then —Natasha, Bum Survivor and Skin

  30. Slide 30: Peer-Reviewed Publications

    Peer-Reviewed Publications 1. "Complete Wound Closure Following a Single Topical Application of a Novel Autologous Homologous Skin Construct: First Evaluation in an Open-Label, Single-Arm Feasibility Study in Diabetic Foot Ulcers” in International Wound Journal 2 Open-label Venous Leg Ulcer Pilot St

  31. Slide 31: SkinTE Regulatory Pathway

    SkinTE Regulatory Pathway Transitioning from _a 361 HCT/P to a 351 HCT/P: SkinTE is currently registered as a human cell, tissue, and cellular and tissue-based product regulated solely under Section 361 of the Public Health Service Act (PHS Act) and 21 CFR Part 1271 (i.e., as a 361 HCT/P). PolarityT

  32. Slide 32: Pipeline

    Pipeline SkinTE POC ——»> Point-of-care device for on-site SkinTE processing and deployment PTE 11000 — === Allogeneic, biologically active dressing for use in wound care mmm Generated To Date 120 PolarityTE, Inc. All Rights Reserved.

  33. Slide 33: Management

    Management Executive Management Team David Seaburg Richard Hague Jacob Patterson Chief Executive Officer, }) President & Chief Interim Chief Financia Orficer WER) Operating Officer 7 Stephen Milner, MD, DDS, DSc, FACS Chief Clinical Officer Edward Swanson, MD Chief Medical Officer & Co-Founder Nikol

  34. Slide 34: Board of Directors

    Board of Directors Peter Cohen, MBA Chairman of the Board Salen Se ce Chris Nolet Director & Chairman of the ‘Audit Committee " prcemateoaseoope: Irrowaton parison Inc. ved, Minnie Baylor-Henry, JD Director aa nage Jeff Dyer, MBA, PhD Director Horace ees fesse of Satan at beg Youn Uneray &te Wharton

  35. Slide 35: Contact Information

    Contact Information PolarityTE Corporate PolarityTE Investor Relations + wwwPolarityTE.com + Rich Haerle, MBA. MPH + [email protected] + VP of Investor Relations + Corporate Inquiries: (800) 378-2694 + IR inquiries: (885) 315-0697 + [email protected] + [email protected] +

  36. Slide 36: About SkinTE™

    About SkinTE™ SkinTE is a human cellular and tissue-based product derived from a patient's own skin (autologous) intended for the repair, reconstruction, replacement, or supplementation of skin tissue. Aseptic surgical procedures and handling during skin harvest, wound preparation, and SkinTE deploy

  37. Slide 37: Company History

    Company History IBEX Pre-clinical ED) ws ht ttt PolarityTE” ae Se a j ‘a VW Matt- ‘Clinical Trials.gov In a terre Poe i Company formed Randomized Tals eported Postve interim i DFU Data from Multi-Center iniTE registered wi Randomized Trial First patent SkinTE registered with FDA application fled 201

  38. Slide 38: References

    References writen i ty en on th care Ce ne en a i dt pe eee ne mene ogee ln fal cto: eared wh th eal of cle sgl wound nth rent and ber ose co sR nino arr de enfrager Vol 221 10 Ot 2016 dot. 1S80/151 84513862811 gl, rr: a Tauraco th United Se pat epoca 2000011" jay vl #7 O10, e884 oO ein TEDL ‘eer ag

PolarityTE — Investor Presentation (September 2020) on 6ix